Drug Trial Radar · NCT07730450
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jul 23, 2026
Primary completion
Aug 20, 2027
Study completion Aug 20, 2027
Sponsor
- Lead sponsor
- BioNTech SEIndustry
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Jul 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age. This study is seeking participants who: * are medically stable * have not had a recent COVID-19 infection * have not had a recent vaccination * do not have medical conditions that increase their risk of complications from COVID-19 All participants in this study will randomly receive 1 injection into their arm of either: * BNT162b2 vaccine which targets COVID-19 and is selected for the 2026-2027 COVID-19 season, or * Tdap vaccine which targets tetanus, diphtheria, and pertussis (whooping cough). The study team and participants will not know which injection they receive. We will evaluate safety and SARS-CoV-2 spike protein levels in people receiving each of these vaccines. Participants will be in the study for about 12 months.
Conditions
- COVID-19 Vaccines
Interventions
BNT162b2 VaccineBiological
Participants will receive a single injection containing variant-adapted BNT162b2 on Day 1.
Tdap VaccineBiological
Participants will receive a single injection containing Tdap on Day 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of participants reporting local reactions or systemic eventsTime frame: From Day 1 up to 7 days after Vaccination
- Percentage of participants reporting adverse eventsTime frame: From Day 1 through 1 month after vaccination
- Percentage of participants reporting serious adverse eventsTime frame: From Day 1 through 12 months after vaccination
- Spike protein levelsTime frame: Up to 12 months after vaccination
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Diablo Clinical Research, LLC dba Flourish Research
Walnut Creek, California · Recruiting
Palm Springs Community Health Center
Miami Lakes, Florida · Recruiting
East-West Medical Research Institute
Honolulu, Hawaii · Recruiting
Duke Vaccine and Trials Unit
Durham, North Carolina · Recruiting
J. Lewis Research, Inc. / Foothill Family Clinic
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.